JP2023541639A - 脂肪酸にコンジュゲートしたオリゴヌクレオチド - Google Patents

脂肪酸にコンジュゲートしたオリゴヌクレオチド Download PDF

Info

Publication number
JP2023541639A
JP2023541639A JP2023516798A JP2023516798A JP2023541639A JP 2023541639 A JP2023541639 A JP 2023541639A JP 2023516798 A JP2023516798 A JP 2023516798A JP 2023516798 A JP2023516798 A JP 2023516798A JP 2023541639 A JP2023541639 A JP 2023541639A
Authority
JP
Japan
Prior art keywords
oligonucleotide
acid acyl
linker
alkyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541639A5 (https=
Inventor
アンデション，シャリニ
ローラン クネール，ダニエル
ミュラース，エリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2023541639A publication Critical patent/JP2023541639A/ja
Publication of JP2023541639A5 publication Critical patent/JP2023541639A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023516798A 2020-09-16 2021-09-15 脂肪酸にコンジュゲートしたオリゴヌクレオチド Pending JP2023541639A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063079179P 2020-09-16 2020-09-16
US63/079,179 2020-09-16
PCT/EP2021/075386 WO2022058386A1 (en) 2020-09-16 2021-09-15 Oligonucleotides conjugated to fatty acids

Publications (2)

Publication Number Publication Date
JP2023541639A true JP2023541639A (ja) 2023-10-03
JP2023541639A5 JP2023541639A5 (https=) 2024-09-24

Family

ID=77989771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516798A Pending JP2023541639A (ja) 2020-09-16 2021-09-15 脂肪酸にコンジュゲートしたオリゴヌクレオチド

Country Status (5)

Country Link
US (1) US20250270248A1 (https=)
EP (1) EP4213883A1 (https=)
JP (1) JP2023541639A (https=)
CN (1) CN116133691A (https=)
WO (1) WO2022058386A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023039522A1 (en) * 2021-09-10 2023-03-16 Guardian Therapeutics, Llc Fatty acid conjugates of nucleic acids
WO2025054459A1 (en) * 2023-09-08 2025-03-13 Dicerna Pharmaceuticals, Inc. Rnai oligonucleotide conjugates
AU2024353921A1 (en) * 2023-09-27 2026-04-16 Neuro3 Therapeutics (Suzhou) Ltd. Novel sirna constructs, therapeutics, and modifications
WO2025250382A1 (en) * 2024-05-31 2025-12-04 University Of Rochester Method and compositions for aptamer mediated delivery of therapeutics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200046846A1 (en) * 2017-03-22 2020-02-13 The Regents Of The University Of California Modified oligonucleotides and therapeutic uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210052631A1 (en) * 2015-09-25 2021-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
JP7665509B2 (ja) * 2018-05-11 2025-04-21 アルファ アノマリック エスアエス ７’－５’－アルファ－アノマー二環式糖ヌクレオシドを含むオリゴヌクレオチドコンジュゲート
WO2021046497A2 (en) * 2019-09-06 2021-03-11 Shen Haifa Orally delivered therapeutical composition and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200046846A1 (en) * 2017-03-22 2020-02-13 The Regents Of The University Of California Modified oligonucleotides and therapeutic uses thereof

Also Published As

Publication number Publication date
CN116133691A (zh) 2023-05-16
US20250270248A1 (en) 2025-08-28
WO2022058386A1 (en) 2022-03-24
EP4213883A1 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
JP2023541639A (ja) 脂肪酸にコンジュゲートしたオリゴヌクレオチド
US11911475B2 (en) Low molecular weight cationic lipids for oligonucleotide delivery
JP5952423B2 (ja) 新規オリゴヌクレオチド接合体およびその用途
US9326941B2 (en) High-efficiency nanoparticle-type double-helical oligo-RNA structure and method for preparing same
CN105705638A (zh) 改善的具有高效能的纳米颗粒型寡核苷酸结构及其制备方法
TW202227135A (zh) 用於遞送治療劑之脂質結合物
JP2023504186A (ja) 標的化された核酸送達のためのペプチドドッキング賦形剤
HK40094171A (zh) 与脂肪酸缀合的寡核苷酸
HK40068097A (en) Novel low molecular weight cationic lipids for oligonucleotide delivery
HK40068097B (en) Novel low molecular weight cationic lipids for oligonucleotide delivery
WO2025223315A1 (zh) 一种用于肝脏特异性递送的多靶标双链rna偶联物及药物组合物
KR101722948B1 (ko) 리간드가 결합된 이중나선 올리고 ｒｎａ 구조체 및 그 제조방법
HK1235682B (en) Low molecular weight cationic lipids for oligonucleotide delivery
TW202521695A (zh) Fto抑制劑組合物及其應用
WO2026046236A1 (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
HK1235682A1 (en) Low molecular weight cationic lipids for oligonucleotide delivery
TW202542148A (zh) 新穎治療性遞送部分及其用途
CN120118900A (zh) 抑制GPAM基因表达的siRNA、其缀合物和药物组合物及用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260428